Paper16100034
Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
Abidi P and 3 others. Arterioscler Thromb Vasc Biol, 2005. Cited by 142 papers, by iCite.
Cite this record
ConductScience Library. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Papers, record 16100034. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16100034
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Berberine | Major topic |
| Extracellular Signal-Regulated MAP Kinases | Major topic |
| Herbal Medicine | Major topic |
| Hypercholesterolemia | Major topic |
| MAP Kinase Signaling System | Major topic |
| Receptors, LDL | Major topic |
| 3' Untranslated Regions | |
| Bile Acids and Salts | |
| Carcinogens | |
| Carcinoma, Hepatocellular | |
| Cell Line, Tumor | |
| Cytomegalovirus | |
| Humans | |
| In Vitro Techniques | |
| Liver Neoplasms | |
| Plasmids | |
| Promoter Regions, Genetic | |
| RNA Stability | |
| RNA, Messenger | |
| Tetradecanoylphorbol Acetate |
Source PubMed
Cited by65
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 142 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943269 | Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease: A Narrative Review. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943269 | PubMed |
| 41745758 | Microcystin-LR Drives Early NAFLD Pathogenesis via Hepatic Cholesterol Accumulation: Dysregulation of Ldlr and Abcg1 Expression Uncoupled from Srebp2. | Toxins (Basel) | 2026 | https://conductscience.org/library/papers/41745758 | PubMed |
| 40881894 | Red yeast rice with monacolin K for the improvement of hyperlipidemia: A narrative review. | World J Clin Cases | 2025 | https://conductscience.org/library/papers/40881894 | PubMed |
| 40506769 | Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. | Eur J Med Res | 2025 | https://conductscience.org/library/papers/40506769 | PubMed |
| 40278960 | Obesity: pathophysiology and therapeutic interventions. | Mol Biomed | 2025 | https://conductscience.org/library/papers/40278960 | PubMed |
| 39021815 | Herbal Products as Complementary or Alternative Medicine for the Management of Hyperglycemia and Dyslipidemia in Patients with Type 2 Diabetes: Current Evidence Based on Findings of Interventional Studies. | J Nutr Metab | 2024 | https://conductscience.org/library/papers/39021815 | PubMed |
| 38034996 | Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38034996 | PubMed |
| 37346213 | Berberine for Adjunct/Alternative Treatment of Dyslipidemia: A Literature Review. | Cureus | 2023 | https://conductscience.org/library/papers/37346213 | PubMed |
| 37240523 | Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia. | J Clin Med | 2023 | https://conductscience.org/library/papers/37240523 | PubMed |
| 36432457 | Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. | Nutrients | 2022 | https://conductscience.org/library/papers/36432457 | PubMed |
| 36381647 | Berberine: Ins and outs of a nature-made PCSK9 inhibitor. | EXCLI J | 2022 | https://conductscience.org/library/papers/36381647 | PubMed |
| 35941413 | Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. | Mol Biol Rep | 2022 | https://conductscience.org/library/papers/35941413 | PubMed |
| 35744831 | Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. | Molecules | 2022 | https://conductscience.org/library/papers/35744831 | PubMed |
| 35337067 | Acanthaster planci Inhibits PCSK9 Gene Expression via Peroxisome Proliferator Response Element (PPRE) and Activation of MEK and PKC Signaling Pathways in Human Liver Cells. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35337067 | PubMed |
| 35334087 | Hypertension and Dyslipidemia Combined Therapeutic Approaches. | High Blood Press Cardiovasc Prev | 2022 | https://conductscience.org/library/papers/35334087 | PubMed |
| 34345932 | Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? | Curr Atheroscler Rep | 2021 | https://conductscience.org/library/papers/34345932 | PubMed |
| 33863898 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. | NPJ Biofilms Microbiomes | 2021 | https://conductscience.org/library/papers/33863898 | PubMed |
| 33019656 | Triciribine Engages ZFP36L1 and HuR to Stabilize LDLR mRNA. | Molecules | 2020 | https://conductscience.org/library/papers/33019656 | PubMed |
| 32789786 | Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies. | Rev Physiol Biochem Pharmacol | 2020 | https://conductscience.org/library/papers/32789786 | PubMed |
| 31915510 | The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway. | Oxid Med Cell Longev | 2019 | https://conductscience.org/library/papers/31915510 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| LDLR | 3949 | PubTator's text mining | https://conductscience.org/library/genes/3949 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16100034
GET https://conductscience.org/api/papers/v1/16100034/cited_by?page=2